TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Utilizing Topical Sodium Hypochlorite to Ameliorate Radiation Dermatitis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years of age or older~* Been diagnosed with head and neck cancer requiring radiation therapy or skin cancer requiring radiation treatment to the neck~* Are scheduled for a radiation therapy planning session (CT simulation)~* Have a scheduled radiation therapy start date within 1 to 2 weeks from the CT simulation~* Are able to comply with the study protocol~Exclusion Criteria:~* Patients who are pregnant, which may lead to discontinuation of radiation therapy~* Patients currently on immunotherapy~* Active or past history of inflammatory lesions in the radiation field that could interfere with assessment~* Patients who are undergoing re-irradiation to the head and neck~* Patients must not have any other condition or situation beyond those listed above which, in the investigator's opinion, puts the patient at significant risk, could confound the study results, or may interfere significantly with the patient's participation in the study.~* Patients who are unable to communicate or cooperate with the investigator due to language problems, poor mental development, or impaired cerebral function are not eligible.~* Participation in other clinical trials that would alter the radiation dose typically utilized for definitive chemo and radiation therapy treatment of head and neck cancer.~* Use of other topical treatments on the skin in the treatment field. No other products are allowed except Aquaphor® ointment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment with Dilute Sodium Hypochlorite solution (Type: EXPERIMENTAL): Subjects will be treated with the dilute bleach compresses daily (Monday through Friday) for the first 3 weeks of therapy. The bleach solution will be prepared and compresses applied for a 20 minute duration prior to radiation therapy. The compress can be applied within an hour of radiation therapy. Subjects will apply Aquaphor® ointment twice a day, once immediately after the radiation treatment and once in the evening. On days the experimental subjects do not receive radiation therapy, they will continue to moisturize their skin twice a day (AM and PM) with Aquaphor® ointment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Anticoagulant Treatments and Percutaneous Coronary Angioplasty

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* stable angina pectoris or silent ischaemia~Exclusion Criteria:~* instable angina or ACS (Acute Coronary Syndrome)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): group without anticoagulant therapy
- 2 (Type: ACTIVE_COMPARATOR): group with heparin
- 3 (Type: ACTIVE_COMPARATOR): group with enoxaparin
- 4 (Type: ACTIVE_COMPARATOR): group with bivalirudin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Persistent Postpartum Hypertension Pilot Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Antepartum diagnosis of gestational hypertension~* preeclampsia~* superimposed preeclampsia without antepartum chronic hypertension medication~* Delivery at 23 weeks or greater~* Persistent elevation in BP \>24 hours postpartum (\>140/90 mm Hg) (2 or more BP \>4 hours apart)~* 18 years or older~* English speaking~Exclusion Criteria:~* Need for continuation of antepartum antihypertensive medication~* Contraindication of calcium channel blocker use~* Severe range (160/110 mm Hg) blood pressure requiring treatment \>24 hours after delivery~* Requires a 2nd oral antihypertensive medication for blood pressure control inpatient~* Acute cardiomyopathy or heart failure~* Creatinine ≥1.5~* Blood pressure \<90/60 within 24 hours of discharge

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Treatment Group (Type: OTHER): The treatment group will be provided with month supply of 30mg tablets of nifedipine extended release prior to discharge from the delivery admission. Dose increases in clinic will be at the discretion of providers, however a treatment algorithm will be provided for guidance.Treatment group will be given a home blood pressure cuff prior to discharge with instructions for use. They will also be scheduled for a 1 week blood pressure check and 4 week postpartum clinic appointment which standard for these patients outside of this proposal.
- Control Group (Type: NO_INTERVENTION): The control group will not receive any medications at discharge. Providers will be instructed to only prescribe new blood pressure medication at subsequent postpartum visits if the blood pressure is in the severe range (\>/=160/110). The control group will be given a home blood pressure cuff prior to discharge with instructions for use. They will also be scheduled for a 1 week blood pressure check and 4 week postpartum clinic appointment which standard for these patients outside of this proposal.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Single Dose Gonadotropin-releasing Hormone (GnRH) Agonist Administration in the Luteal Phase of GnRH Antagonist Stimulated ICSI-ET Cycles

Study Design Characteristics:
- Allocation: N/A
- Intervention Model: N/A
- Observational Model: N/A
- Primary Purpose: N/A
- Time Perspective: N/A
- Masking: N/A
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Women undergoing embryo transfer following controlled ovarian hyperstimulation with a fixed GnRH antagonist protocol, oocyte pick-up and ICSI.~* Embryo transfer performed on day 3~Exclusion Criteria:~* Participation in another trial that was being conducted in our unit at the same time.~* Preimplantation genetic screening cycles.~* Day 5 embryo transfers.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- GnRH agonist (Type: EXPERIMENTAL): None
- Saline (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Ranolazine on Gastrointestinal Motor Function and Pain in Patients With IBS-D

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~* Males and non-pregnant, non-breastfeeding females with established diagnosis of IBS-D by modified Rome III criteria (Abdominal Pain Intensity: weekly average of worst daily score of \>3.0 on a 0 to 10 point scale and Stool Consistency: at least one stool with a consistency of Type 5, 6 or 7 Bristol stool score on at least 2 days per week)~* 18-70 years old~* U.S. resident~* English-speaking (to provide consent and complete questionnaires)~Exclusion Criteria~* Structural or metabolic diseases/conditions that affect the gastrointestinal system~* Unable to withdraw the following medications 48 hours prior to the study:~  * Drugs that alter GI transit including Lomotil, and bile acid binders such as cholestyramine, prokinetics (e.g. metoclopramide, cisapride and erythromycin), narcotics (e.g. oxycodone, morphine) and anticholinergics (dicyclomine, hyoscyamine).~ * Analgesic drugs including narcotics, NSAID, cyclooxygenase-2 ( COX2) inhibitors (celecoxib, rofecoxib, and valdecoxib)~ * GABAergic agents (baclofen)~ * Benzodiazepines (e.g. lorazepam, alprazolam, and diazepam). Low stable doses of thyroid replacement, estrogen replacement, and low dose aspirin for cardioprotection and birth control pills or depot injections are permissible.~* Unable to withdraw the following medications, which are contraindications of ranolazine:~  * Strong Cytochrome P450, Family 3, Subfamily A (CYP3A) inhibitors (e.g. ketoconazole, clarithromycin, and nelfinavir)~ * CYP3A inducers (e.g. rifampin, phenobarbital, St. John's wort)~* Female subjects who are pregnant or breastfeeding.~* Current symptoms of severe depression, as measured by Hospital Anxiety And Depression Scale ( HADS) score greater than 15.~* Clinical evidence (including physical exam, ECG, laboratory studies and review of the medical history) of significant cardiovascular, respiratory, renal, hepatic, gastrointestinal, hematological, neurological, psychiatric, or other disease that interfere with the objectives of the study.~* The Corrected QT Interval (QTc) \> 490 msec.~* Active alcoholics not in remission or known substance abusers.~* Liver cirrhosis~* Patients with clinically significant hepatic disease.~* Major cardiovascular events in the last 6 months.~* Participation in another clinical trial (within 30 days).~* Incarcerated.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Ranolazine (Type: ACTIVE_COMPARATOR): tablet, 1000 mg twice daily for four weeks
- Placebo (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Multicentre Registry of Treatments and Outcomes in Patients With Chronic Lymphocytic Leukaemia (CLL) Or Indolent Non Hodgkin's Lymphoma (iNHL)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Informed consent~* CLL patients or~* iNHL patients~* Clinical decision made to initiate or adapt treatment of CLL/iNHL(Need to treat)~Exclusion Criteria:~* Patient deemed unfit for enrollment by the documented opinion of the investigator~* Watch and wait patients~* Richter's transformation~* Patients otherwise not eligible for (pharmacological) intervention~* Moribund patients

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment naïve patients with CLL (Type: None): None
- Treatment naïve patients with iNHL (Type: None): None
- Relapsed/refractory patients with CLL (Type: None): None
- Relapsed/refractory patients with iNHL (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Curcumin Formulation in Alzheimer's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or Female age ≥ 50.~* Diagnosed with probable AD using NINDS-ADRDA research criteria. MMSE score ≥5 and ≤20.~* No history of significant psychiatric or non-AD neurological disease.~* An available caregiver to monitor and administer medication and to accompany the subject to every clinical visit.~* On stable doses of concomitant medications for at least one month prior to starting study medication.~Exclusion Criteria:~* Current or recent major psychiatric illness that meets DSM-IV criteria (i.e. bipolar disorder, schizophrenia).~* Significant uncontrolled systemic illness (i.e. chronic renal failure, chronic liver disease, poorly controlled diabetes, or poorly controlled congestive heart failure).~* Recent history of gastrointestinal bleeding or ulceration.~* Alcoholism or substance abuse within the past year per DSM-IV criteria.~* Familial, autosomal dominant Alzheimer's disease due to a mutation in a known gene (Presenilin-1, Presenilin-2, or Amyloid Precursor Protein).

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- curcumin (Type: ACTIVE_COMPARATOR): None
- placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Freehand Ultrasound Elasticity Imaging in Liver Surgery

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Any patient eligible for open, laparoscopic, or percutaneous hepatic RFA or MWA as their surgical treatment due to either primary tumors of the liver as well as liver metastases.~* Participants must be able to have post-operative CT/MRI at Johns Hopkins as their standard care.~Exclusion Criteria:~* Patients under 18 years old.~* Pregnant women.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- IOUS-USEI (Type: None): Receive intraoperative ultrasound (IOUS) using the Siemens Anteras to acquire ultrasound elasticity imaging (USEI) during standard of care surgical radiofrequency ablation and microwave ablation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Metabolic Response to Infliximab in Pediatric Ulcerative Colitis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female children between the ages of six and eighteen years of age~* Endoscopic or histologic evidence of ulcerative colitis~* Active ulcerative colitis determined by primary pediatric gastroenterologist to require anti-tumor necrosis factor-alpha antibody (infliximab) therapy~* Colitis symptom score ≥2~* Screening laboratory tests that meet the following criteria (obtained within 4 weeks of enrollment):~  1. Hemoglobin \>8.0 g/dL~ 2. White blood cell count \>3.5 x 109/L~ 3. Neutrophils \>1.5 x 109/L~ 4. Platelets \>100 x 109/L~ 5. Aspartate aminotransferase, alanine aminotransferase, and alkaline phosphatase levels within 3 times the upper limit of normal.~ 6. PPD skin test with skin induration \<5 mm.~ 7. Signed written consent from the parent/legal guardian and assent from the child to be obtained prior to enrollment.~Exclusion Criteria:~* Female subjects who are pregnant, nursing, or planning pregnancy.~* Concomitant diagnosis or history of congestive heart failure.~* Serious infection in the 3 months prior to enrollment.~* History of prior or current active or latent tuberculosis.~* Immune deficiency syndrome, including documented human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS).~* History of systemic lupus erythematosus.~* A transplanted organ.~* Known malignancy or history of malignancy within 5 years of enrollment.~* History of demyelinating disease.~* History of substance abuse.~* History of diabetes mellitus.~* Poor tolerability of venipuncture or lack of venous access during the study period.~* A live virus vaccination within 3 months of enrollment.~* Prior history of infliximab infusion or any other therapeutic agent targeted at reducing tumor necrosis factor-alpha (TNF-alpha).~* Hypersensitivity to any murine proteins or other component of the product.~* Inability to comply with study procedures

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Infliximab (Type: OTHER): Subjects on infliximab

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Inhaled Nitric Oxide and Neuroprotection in Premature Infants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Prematurity (birthweight ≤ 1500g, \< 31 weeks gestation)~* Requiring respiratory support~* Admitted to the NICU at the University of Chicago~Exclusion Criteria:~* Severe congenital anomalies~* Genetic syndromes~* Extremely sick preterm infants requiring very high ventilatory pressures (OI ≥ 20)~* Premature infants judged by the physician as nonviable

- Gender: ALL
- Minimum Age: 2 Hours
- Maximum Age: 72 Hours
- Healthy Volunteers: f

Study Arms:
- INO Control (Short iNO) (Type: PLACEBO_COMPARATOR): INO will be given to infants in the control group for the first 7 days of the study gas, then O2 or room air, as clinically appropriate, on the 8th day, until 33 weeks corrected age
- INO Treatment (Long iNO) (Type: EXPERIMENTAL): The treatment group will receive iNO, combined with O2 or room air, until 33 weeks corrected age.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Hyperbaric Oxygen as an Adjuvant Treatment for Patients With Covid-19 Severe Hypoxemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years, all sexes.~* No previous hospitalizations in the last 6 months.~* Positive diagnostic test for COVID-19 according to the guidelines of the Argetine Ministry of Health at the time of enrollment.~* Patient in Intensive Care Unit with oxygen need: Need for continuous supply of oxygen to maintain saturation by oximetry pulse (SpO2) greater than or equal to 93% or arterial gas with PaO2 value greater than 60 mmHg~Exclusion Criteria:~* 18 years of age.~* Person unable to give consent.~* Person who refuses to participate.~* Pregnancy and lactation~* Participating in other study~* Requirement for mechanical ventilation.~* Inability to maintain prolonged sitting position (at least 2 hours)~* Subject with contraindications to HBOT (pulmonary shock, bullae, emphysema or untreated pneumothorax, severe seizures, uncontrolled hypertension, chronic obstructive disease of grade III or IV).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Experimental HBOT (Type: EXPERIMENTAL): Treatment (device). Patients will receive 90 minutes of hyperbaric oxygen at 1,45 ATA in a Revitalair430 hyperbaric chamber, and then they will continue with standard care and normobaric oxygen.
- Standard care (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Platelet-rich Plasma (PRP) for Endometrial Regeneration and Repair

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Persistent thin lining \< 6mm on \>1 cycle in previous IVF or FET cycle OR moderate-to-severe Asherman's syndrome~Exclusion Criteria:~* Age \<18 years old or \>43 years old,~* Pregnancy,~* Diagnosis of cancer,~* Hb \<11 g/dL, platelets \<150,000/mm3,~* Anticoagulation,~* NSAIDs in the 10 days before procedure~* Any significant comorbidity or psychiatric disorder that would compromise patient safety or compliance, interfere with consent, study participation, follow up, or interpretation of study results.~* Incision in the uterus: myomectomy; cesarean section

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 43 Years
- Healthy Volunteers: t

Study Arms:
- PRP intrauterine infusion (Type: EXPERIMENTAL): Intrauterine infusion of platelet rich plasma in combination with standard treatment, in patients with Asherman's Syndrome or thin uterine lining in frozen embryo transfer cycles
- Control group with standard treatment only (Type: NO_INTERVENTION): Patients with Asherman's Syndrome or thin uterine lining in frozen embryo transfer cycles undergoing standard treatment protocols

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues